Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Wyeth has said that an FDA inspection of its Guayama, Puerto Rico manufacturing facility is expected to take at least several more weeks to complete.
Subscribe to our email newsletter
The inspection of the site began in late January 2007 and is related to an FDA Warning Letter received in May 2006 that raised several specific concerns about manufacturing at the Guayama facility. Production at the plant has been reduced as a result of the inspection.
As previously noted, Wyeth has undertaken a corrective action plan to improve compliance at the plant which manufactures birth control pills, hormone replacement drugs, antidepressants and over-the-counter pain relievers.
Wyeth also reaffirmed its 2007 full year pro forma diluted earnings per share guidance of $3.40 to $3.50, an increase of 8% to 11% over 2006.